India - UK FTA provisions favor neither India nor the UK except the pharma industry in a big way. It defeats the firm stand taken by the Indian PM three years ago when he decided to pull out of the RCEP against the corporate interests over people’s lives.
UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely.
After the Comprehensive Economic Cooperation Agreement signed between India and Australia, the domestic pharmaceutical industry is seeing a plethora of opportunities for international trade.
On farmers and food, vaccine inequality, climate justice and digital rights, we need to act in solidarity – and not allow trade rules to sacrifice people to corporate profit.
Even without an IP waiver from the WTO, China and India are leading the challenge to the West’s vaccine monopoly.
Potential BIT claims by foreign pharmaceutical companies against India for the revocation, suspension or non-enforcement of IPRs could undermine the benefits of a potential TRIPS waiver.
India is seeking concessions for generic drugs it exports to the United States in return for opening its dairy markets and slashing tariffs on farm goods as the two sides seek to shore up a new trade deal.
In order to halt the spread of the coronavirus pandemic (Covid-19) and to boost the public health care system and preparedness, India has taken several regulatory steps.
US-India IP engagements since 2006 have served the interests of the US through systematic undermining of the legislative safeguards in the Indian Patents Act.
India and Indonesia are set to launch negotiations for a Comprehensive Economic Cooperation Agreement (CECA) to cover economic cooperation while trading in goods, services, and investments.
A Free Trade Agreement with the US will likely result in the amendment of the Patents Act, which could impact the Indian pharma industry.
Officials from the European Union (EU) and India are expected to meet in Brussels on April 12th to resume technical talks on the long-stalled EU-India free trade agreement (FTA). A leaked draft of the agreement, which has been under discussion since 2007, contains proposals from the EU that push for intellectual property (IP) provisions in the FTA that could jeopardize access to affordable medicines.
India must resist pressure from Japan and South Korea in RCEP for the elevated levels of intellectual property provisions and make sure the deal doesn’t limit the production of life-saving generic drugs in India and for many other developing countries of the world.
India and Cambodia clinch a deal to work towards a Bilateral Investment Treaty which provides financial help to Southeast Asian nations.
India may have to lower the import duty on pharmaceuticals for Peru in the discussions on the proposed free trade agreement (FTA) with the South American country.
The present Indian government has relaunched the talks with Israel. Israel wishes to conduct talks on regular basis to conclude the deal at the earliest. Indian patent system and pharmaceutical related issues have been the reasons why the deal couldn’t progress.
India’s position in the RCEP is the most protectionist among all the member nations. India has been resisting demands from Korea & Japan on intellectual property clauses, and other nations on opening up markets.
If the trade equation between India and Peru is in imbalance it would be causing more harm than benefit to India.
India firm in opposing proposals that could hinder global access to affordable generic drugs
Healthcare watchers are calling on India to resist RCEP